7,507.47

-42.47

-0.56%

52,213.25

-176.50

-0.34%

24,985.64

-267.50

-1.06%

2,816.00

-24.81

-0.87%

4.9920

+0.1280

+2.63%

20.05

+0.13

+0.65%

4,038.40

-76.10

-1.85%

73,274.44

-1,504.56

-2.01%

Crude Oil Dec 26

86.07

-0.78

-0.90%

US Private Equity

10,850.15

0.00

0.00%

NasdaqCM - Nasdaq Real Time Price USD

Alzamend Neuro, Inc. (ALZN)

1.4054 -0.0146 (-1.03%)

As of 2:09:49 PM EST. Market Open.

Loading Chart for ALZN

Chart Range Bar

Interval:

In partnership with ChartIQ

Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?

Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?

Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Alzamend Neuro Initiates Phase II Clinical Trial of AL001

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?

EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?

Mobilize your Website

View Site in Mobile | Classic

Share by: